Clovis's rucaparib shows 'BRCAness' in interim Phase II
This article was originally published in Scrip
Executive Summary
Interim results from the Phase II ARIEL2 clinical trial for Clovis Oncology's PARP inhibitor rucaparib seem to show that the oral drug is effective in relapsed ovarian cancer patients beyond those who have BRCA mutations and are sensitive to platinum-containing chemotherapy.